Fox Run Management’s Ginkgo Bioworks DNA Stock Holding History

Fox Run Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-13,407	Closed	-$76.4K	–	950
2025 Q1	$76.4K	Buy	+13,407	New	+$137K	0.01%	865

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fox Run Management's DNA Position: Q2 2025 in Review

Fox Run Management sold out of Ginkgo Bioworks (DNA) in Q2 2025, closing a stake of 13,407 shares — an estimated $76.4K sold.

Fox Run Management first reported a position in DNA in Q1 2025 and held it in 1 quarter. The position peaked at $76.4K in Q1 2025. 166 funds tracked by Wall St. Rank hold DNA as of Q2 2025.

Fox Run Management reported no remaining Ginkgo Bioworks position as of Q2 2025 after selling out during the quarter.
Fox Run Management sold 13,407 Ginkgo Bioworks shares in Q2 2025, an estimated $76.4K.
Fox Run Management first reported a position in Ginkgo Bioworks in Q1 2025 and held it in 1 quarter.
Fox Run Management's Ginkgo Bioworks position peaked at $76.4K in Q1 2025.
166 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2025.

Based on Fox Run Management's 13F filing for Q2 2025, filed 6 Aug 2025.